Duchesnay Pharmaceutical selected as one of the first participants in federal government’s Global Hypergrowth Project
by CM staff
The GHP is a new initiative that aims to ensure that the government supports are in place to help Canadian firms grow.
Photo: Duchesnay Pharmaceutical.
BLAINVILLE — Duchesnay Pharmaceutical Group has been named to join the inaugural cohort of the Government of Canada’s Global Hypergrowth Project (GHP).
The announcement of the winners of the competition was made in Toronto by Mary Ng, federal Minister of International Trade, Export Promotion, Small Business and Economic Development.
The GHP is a new initiative that aims to ensure that the government supports are in place to help Canadian firms grow. Through a selection process, firms were assessed based on their demonstrated potential to execute on growth ambitions and on their potential to contribute to building greater communities, greater jobs and growth in Canada.
“Duchesnay Pharmaceutical Group is very pleased that its success and growth have been recognized by being named to the GHP, as well as the great potential we have for further expansion, in Canada and in other countries as we expand our international footprint,” said Éric Gervais, President of Duchesnay Pharmaceutical Group. “We are very proud of the success we have already achieved but look forward to partnering with the GHP to propel our growth to make our innovative, Canadian-manufactured pharmaceuticals available to more patients around the world.”
As one of the eight companies named to the GHP, Duchesnay Pharmaceutical Group will be assigned a dedicated GHP account executive to provide support where it is needed in key areas such as funding growth, international expansion, talent acquisition, navigation of federal regulations, access to procurement projects, mentorship and expertise. As well, the GHP will co-develop and execute a service plan to help companies work with all levels of government, agencies and Crown corporations to assist company growth in any way, as well as to develop a communications strategy to celebrate the companies’ successes.
“The GHP is an excellent opportunity for Duchesnay Pharmaceutical Group to supercharge its growth, particularly in export markets, therefore creating more Canadian jobs,” said Mélanie Therrien, Vice-President, Finance, of Duchesnay Pharmaceutical Group. “We can use the intellectual property that we developed and own to benefit more patients around the world while also creating economic success in Canada.”
